Instrument Inactif

Communiqués Applied DNA Sciences Inc OTC Bulletin Board

Actions

US03815U1025

Gestion des placements et exploitants de fonds

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

15/05	BNB Plus Corp. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 31 mars 2026	CI
21/04	BNB Plus Corp annonce une revue de ses alternatives stratégiques afin de maximiser la valeur actionnariale	CI

Communiqués

26/05	BNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic Financing	BU
15/05	BNB Plus: Fiscal Q2 Earnings Snapshot	AQ
23/04	BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order	BU
20/04	BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value	BU
18/03	BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform	BU
24/02	BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers	BU
12/02	BNB Plus: Fiscal Q1 Earnings Snapshot	AQ
05/02	BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director	BU
27/01	BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th	BU
27/01	BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th	AQ
05/01	BNB Plus Corp. (BNBX) Receives $1.2M Accelerated LineaDNA™ Order	BU
22/12	BNB Plus : Annual Report for Fiscal Year Ending 09-30, 2025 (Form 10-K)	PU
18/12	BNB Plus Corp. (BNBX) Announces Largest Ever Shipment of LineaDNATM	BU
09/12	BNB Plus Provides BNB Treasury and Operational Updates	BU
17/11	Applied DNA Rebrands as BNB Plus Corp., Elects Josh Kruger as Chairman of the Board	BU
28/10/25	BNBX Launches Digital Asset Treasury Dashboard and Provides Corporate Update	BU
22/10/25	Applied DNA Sciences Closes up to $58 Million Private Placement; Announces Initial BNB Holdings Valued at Over $17 Million	BU
15/10/25	Applied DNA Sciences Becomes a B2i Digital Featured Company to Share Its Strategic Rebrand and BNB-Focused Treasury Shift With Investors	AQ
06/10/25	Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX’ Reflecting Digital Asset Treasury Strategy	BU
29/09/25	Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation	BU
14/08/25	Applied DNA Sciences: Fiscal Q3 Earnings Snapshot	AQ
08/07/25	Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements	AQ
15/05/25	Applied DNA Sciences: Fiscal Q2 Earnings Snapshot	AQ
21/04/25	Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA	AQ
09/04/25	Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement	AQ